BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 27573663)

  • 1. Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.
    Lassaletta A; Scheinemann K; Zelcer SM; Hukin J; Wilson BA; Jabado N; Carret AS; Lafay-Cousin L; Larouche V; Hawkins CE; Pond GR; Poskitt K; Keene D; Johnston DL; Eisenstat DD; Krishnatry R; Mistry M; Arnoldo A; Ramaswamy V; Huang A; Bartels U; Tabori U; Bouffet E
    J Clin Oncol; 2016 Oct; 34(29):3537-3543. PubMed ID: 27573663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
    Bouffet E; Jakacki R; Goldman S; Hargrave D; Hawkins C; Shroff M; Hukin J; Bartels U; Foreman N; Kellie S; Hilden J; Etzl M; Wilson B; Stephens D; Tabori U; Baruchel S
    J Clin Oncol; 2012 Apr; 30(12):1358-63. PubMed ID: 22393086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
    Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
    Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of centrally located low-grade glioma in children.
    Terashima K; Chow K; Jones J; Ahern C; Jo E; Ellezam B; Paulino AC; Okcu MF; Su J; Adesina A; Mahajan A; Dauser R; Whitehead W; Lau C; Chintagumpala M
    Cancer; 2013 Jul; 119(14):2630-8. PubMed ID: 23625612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH).
    Gnekow AK; Kortmann RD; Pietsch T; Emser A
    Klin Padiatr; 2004; 216(6):331-42. PubMed ID: 15565548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
    Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
    Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of combination carboplatin and vinblastine for pediatric low-grade glioma.
    Nellan A; Wright E; Campbell K; Davies KD; Donson AM; Amani V; Judd A; Hemenway MS; Raybin J; Foreman NK; Rush S; Dorris K
    J Neurooncol; 2020 Jul; 148(3):569-575. PubMed ID: 32506370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metronomic Maintenance With Weekly Vinblastine After Induction With Bevacizumab-Irinotecan in Children With Low-grade Glioma Prevents Early Relapse.
    Roux C; Revon-Rivière G; Gentet JC; Verschuur A; Scavarda D; Saultier P; Appay R; Padovani L; André N
    J Pediatr Hematol Oncol; 2021 Jul; 43(5):e630-e634. PubMed ID: 33235152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group.
    Ater JL; Xia C; Mazewski CM; Booth TN; Freyer DR; Packer RJ; Sposto R; Vezina G; Pollack IF
    Cancer; 2016 Jun; 122(12):1928-36. PubMed ID: 27061921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
    Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Guerreiro Stucklin A; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang S; Snuderl M; Nageswara Rao A; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Faure Conter C; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser P; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen S; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U
    J Clin Oncol; 2017 Sep; 35(25):2934-2941. PubMed ID: 28727518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study.
    Jakacki RI; Bouffet E; Adamson PC; Pollack IF; Ingle AM; Voss SD; Blaney SM
    Neuro Oncol; 2011 Aug; 13(8):910-5. PubMed ID: 21764821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Dabrafenib in Pediatric Patients with
    Hargrave DR; Bouffet E; Tabori U; Broniscer A; Cohen KJ; Hansford JR; Geoerger B; Hingorani P; Dunkel IJ; Russo MW; Tseng L; Dasgupta K; Gasal E; Whitlock JA; Kieran MW
    Clin Cancer Res; 2019 Dec; 25(24):7303-7311. PubMed ID: 31811016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
    Hurwitz CA; Strauss LC; Kepner J; Kretschmar C; Harris MB; Friedman H; Kun L; Kadota R
    J Pediatr Hematol Oncol; 2001; 23(5):277-81. PubMed ID: 11464982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single agent carboplatin for pediatric low-grade glioma: A retrospective analysis shows equivalent efficacy to multiagent chemotherapy.
    Dodgshun AJ; Maixner WJ; Heath JA; Sullivan MJ; Hansford JR
    Int J Cancer; 2016 Jan; 138(2):481-8. PubMed ID: 26235348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
    Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
    J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trametinib for progressive pediatric low-grade gliomas.
    Kondyli M; Larouche V; Saint-Martin C; Ellezam B; Pouliot L; Sinnett D; Legault G; Crevier L; Weil A; Farmer JP; Jabado N; Perreault S
    J Neurooncol; 2018 Nov; 140(2):435-444. PubMed ID: 30097824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial.
    Haas-Kogan DA; Aboian MS; Minturn JE; Leary SES; Abdelbaki MS; Goldman S; Elster JD; Kraya A; Lueder MR; Ramakrishnan D; von Reppert M; Liu KX; Rokita JL; Resnick AC; Solomon DA; Phillips JJ; Prados M; Molinaro AM; Waszak SM; Mueller S
    J Clin Oncol; 2024 Feb; 42(4):441-451. PubMed ID: 37978951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history and outcome of optic pathway gliomas in children.
    Nicolin G; Parkin P; Mabbott D; Hargrave D; Bartels U; Tabori U; Rutka J; Buncic JR; Bouffet E
    Pediatr Blood Cancer; 2009 Dec; 53(7):1231-7. PubMed ID: 19621457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
    Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
    Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.
    Karajannis MA; Legault G; Fisher MJ; Milla SS; Cohen KJ; Wisoff JH; Harter DH; Goldberg JD; Hochman T; Merkelson A; Bloom MC; Sievert AJ; Resnick AC; Dhall G; Jones DT; Korshunov A; Pfister SM; Eberhart CG; Zagzag D; Allen JC
    Neuro Oncol; 2014 Oct; 16(10):1408-16. PubMed ID: 24803676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.